Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Lurbinectedin Makes a Splash in Second-Line SCLC

April 5th 2021

Wade T. Iams, MD, discusses the efficacy and safety of lurbinectedin in patients with small cell lung cancer, the impact of its approval on the paradigm, and remaining questions regarding its use.

Dr. Subramanian on the Efficacy of Selpercatinib in RET+ NSCLC

April 2nd 2021

Janakiraman Subramanian, MD, discusses the efficacy of selpercatinib in patients with RET fusion–positive non–small cell lung cancer.

Emerging Agents and Future of Small Cell Lung Cancer

April 2nd 2021

Jared Weiss, MD, and Stephen V. Liu, MD discuss treatment of small cell lung cancer and therapies in the pipeline.

Management of ES-SCLC: Second Line and Beyond

April 2nd 2021

Considerations for second-line treatment regimens, the role of immunotherapy in the relapsed/refractory setting, and using lurbinectedin for the management of ES-SCLC.

Using Trilaciclib for Treatment of ES-SCLC

April 2nd 2021

Stephen V. Liu, MD, and Jared Weiss, MD, share their thoughts on the impact of the recent approval of trilaciclib prior to platinum/etoposide-based chemotherapy for the treatment of ES-SCLC.

Patritumab Deruxtecan Under Exploration in Phase 2 HERTHENA-Lung01 Trial for EGFR+ NSCLC

April 1st 2021

The HER3-directed antibody-drug conjugate patritumab deruxtecan is under exploration in the treatment of patients with EGFR-mutated, metastatic or locally advanced non–small cell lung cancer who had previously received a TKI and platinum-based chemotherapy.

OncLive® Takes a Look Back at Most Listened Podcasts of 2020

April 1st 2021

Digital media, now more than ever, has become a primary platform for communication, and in 2020, the production of the OncLive® podcast, OncLive On Air™, was put into overdrive to bring practicing oncologists exclusive biweekly interviews, discussions, and insights from leading experts in cancer care.

Dr. Heymach on the Future of Immunotherapy in NSCLC

March 31st 2021

John V. Heymach, MD, PhD, discusses the future of immunotherapy in patients with non–small cell lung cancer.

Dr. Porter on Potential Sequencing With ADCs and TKIs in HER2+ Lung Cancer

March 31st 2021

Jason Porter, MD, discusses potential sequencing strategies with antibody-drug conjugates and TKIs in HER2-positive lung cancer.

Dr. Bazhenova on the Importance of Testing for HER2 Mutations in Lung Cancer

March 31st 2021

Lyudmila A. Bazhenova, MD, discusses the importance of testing for HER2 mutations in lung cancer.

Dr. Raez on the Impact of PD-L1 Status on Immunotherapy Outcomes in NSCLC

March 30th 2021

Luis E. Raez, MD, discusses the impact of PD-L1 status on immunotherapy outcomes for patients with non–small cell lung cancer.

Dr. Wozniak on Optimizing the Use of Immunotherapy in NSCLC

March 30th 2021

Antoinette Wozniak, MD, FACP, FASCO, discusses optimizing the use of immunotherapy in patients with non–small cell lung cancer.

Hu Highlights Recent Advances and Approvals in RET-Altered Thyroid Cancer

March 29th 2021

Dr. Hu discusses the importance of testing for RET alterations in thyroid cancer, the FDA approvals of selpercatinib and pralsetinib, and the changing dynamics between medical oncologists and endocrinologists.

Dr. Johnson on the Clinical Potential of AMG 757 in SCLC

March 29th 2021

Melissa L. Johnson, MD, discusses the clinical potential of AMG 757 in patients with small cell lung cancer.

Advances in Targeting MET Exon 14 Skipping Mutations in NSCLC

March 29th 2021

Drs Joshua M. Bauml and Benjamin Levy react to the development of novel therapies that specifically target MET exon 14 skipping mutations in non–small cell lung cancer.

MET Exon 14 Skipping Mutations in NSCLC

March 29th 2021

Drs Joshua M. Bauml and Lyudmila A. Bazhenova describe what is understood regarding the behavior of MET exon 14 skipping mutations in non–small cell lung cancer and remark on their prevalence among specific patient populations.

Dr. Ramalingam on Treatment After Osimertinib in EGFR-Mutant NSCLC

March 27th 2021

Suresh S. Ramalingam, MD, FASCO, deputy director, director, Lung Cancer Program, Winship Cancer Institute of Emory University, professor, assistant dean, Roberto C. Goizueta Distinguished Chair for Cancer Research, director, Division of Medical Oncology, Department of Hematology and Medical Oncology, Emory University School of Medicine, discusses treatment after osimertinib (Tagrisso) in EGFR-mutant non–small cell lung cancer (NSCLC).

Durvalumab Use Differs in Real-World, PACIFIC Stage III NSCLC Populations

March 27th 2021

More patients with stage III non–small cell lung cancer received sequential chemoradiation and delayed the time to durvalumab treatment in a real-world setting compared with those enrolled on the phase 3 PACIFIC trial.

Dr. Subramanian on Real-World Data With EGFR TKIs in Advanced NSCLC

March 27th 2021

Janakiraman Subramanian, MD, discusses the use of EGFR TKIs in the treatment of patients with non–small cell lung cancer.

Frontline Osimertinib Showcases Real-World Safety, Efficacy in EGFR+ Advanced NSCLC

March 27th 2021

Osimertinib (Tagrisso) showcased encouraging efficacy and acceptable safety in patients with EGFR-positive, advanced non–small cell lung cancer. according to real-world findings from an observational, multicenter study.